Cardinal Health (CAH) Earnings Date & Reports

Key Takeaways

• Consensus estimates point to continued growth: Analysts expect Cardinal Health to report Q4 fiscal 2026 earnings of $2.42 per share, a 16.4% increase from $2.08 in the same quarter last year, on revenue of approximately $65.6 billion.
• Strong earnings beat track record: CAH has surpassed Wall Street EPS expectations in each of the last four quarters, delivering an average earnings surprise of roughly 10%.
• Specialty pharmaceuticals remain the growth engine: The Pharmaceutical and Specialty Solutions segment is expected to drive results, with specialty revenue growing over 20% and on track to exceed $50 billion for the full fiscal year.
• Tariff and cost pressures linger: The Global Medical Products and Distribution (GMPD) segment faces ongoing headwinds from tariffs, inflationary pressures, and selective customer volume losses.
• Raised full-year guidance sets high bar: Management lifted its fiscal 2026 non-GAAP EPS (earnings per share excluding certain one-time items) guidance to $10.70–$10.80, reflecting confidence but also raising expectations for the Q4 print.
• Analyst sentiment remains bullish: The stock carries a consensus "Strong Buy" rating with an average 12-month price target of approximately $252, implying modest upside from current levels near $236.

Earnings Context and Why It Matters

Cardinal Health's fourth-quarter fiscal 2026 report, scheduled for release before the market opens on August 11, serves as the company's year-end summary and a critical check-in on its multi-year transformation strategy. As one of the largest pharmaceutical distributors in the United States, CAH sits at the intersection of several powerful healthcare trends — rising specialty drug utilization, GLP-1 (glucagon-like peptide-1) medication adoption, biosimilar expansion, and shifts in reimbursement policy under the Inflation Reduction Act. The company has delivered robust operational momentum throughout fiscal 2026, raising guidance twice. Investors will scrutinize this report for signs that specialty growth, free cash flow generation, and margin expansion can be sustained heading into fiscal 2027, particularly against a backdrop of tariff uncertainty and evolving drug pricing dynamics.

Earnings Expectations

Wall Street analysts have set the bar for Cardinal Health's fiscal fourth quarter at $2.42 in earnings per share, according to consensus estimates tracked by Zacks, reflecting approximately 16.4% year-over-year growth from the $2.08 reported in Q4 fiscal 2025. Revenue is expected to land near $65.6 billion, representing roughly 9.1% growth from the prior-year quarter. GAAP (Generally Accepted Accounting Principles) EPS estimates stand at approximately $1.85 per share, reflecting the impact of one-time items including goodwill impairments and restructuring costs.

At the segment level, analysts project the Pharmaceutical and Specialty Solutions unit to deliver revenue of approximately $61.0 billion, up about 10% year-over-year, with segment profit estimated at $628 million. The Global Medical Products and Distribution segment is expected to contribute roughly $3.3 billion in revenue, while the company's Other growth businesses — which include At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics — are projected to generate about $1.8 billion in revenue.

It is worth noting that Cardinal Health has consistently outperformed expectations. In the most recent third quarter, the company posted non-GAAP EPS of $3.17, beating estimates by $0.38, driven by above-expectation performance in specialty pharmaceuticals and the Other growth businesses. The company's Q4 report will also confirm whether it achieved its raised full-year non-GAAP EPS target of $10.70 to $10.80, which implies roughly 30% to 31% annual EPS growth.

AI Screener

For investors and traders seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful, AI-driven solution for navigating the broader market. The AI Screener is an advanced stock and ETF discovery tool that enables users to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Whether scanning for breakout candidates, trending stocks, or under-the-radar opportunities within the healthcare distribution sector, the screener delivers actionable insights with greater speed and precision than manual research methods. Traders can tailor filters to their specific strategy and uncover trade ideas aligned with current market conditions. Discover how the AI Screener can enhance your market research workflow today.

Market Reaction and Investor Sentiment

Investor sentiment heading into Cardinal Health's Q4 report leans positive but cautious. CAH shares have rallied more than 15% year-to-date, significantly outperforming both the S&P 500 and the broader healthcare sector, reflecting confidence in the company's specialty expansion and free cash flow trajectory. The stock closed at $236.40 on August 7, trading near the upper end of its 52-week range and above both its 50-day and 200-day moving averages.

However, the elevated valuation — with a forward price-to-earnings (P/E) multiple near 20 times — leaves limited room for disappointment. Key risk factors heading into the print include GMPD segment margin pressures from tariffs, uncertainty around potential tariff refunds, the impact of Inflation Reduction Act-related drug pricing changes on pharmaceutical distribution revenue, and moderating GLP-1 growth rates. On the flip side, sustained specialty revenue growth above 20%, stronger-than-expected free cash flow, and any positive commentary on fiscal 2027 guidance could serve as catalysts for further upside. The options market implies a post-earnings move of approximately 4% to 5% in either direction, consistent with historical volatility around CAH earnings events.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q4 print, several themes will shape Cardinal Health's trajectory into fiscal 2027. The company's specialty pharmaceutical platform — anchored by the Solaris integration, the Specialty Alliance physician network, and expanded biosimilar capabilities — remains the central growth narrative. Management's target of specialty revenue exceeding $50 billion in fiscal 2026 sets a baseline from which investors will gauge next year's growth runway.

Tariff policy presents a double-edged risk. Cardinal Health has already paid approximately $200 million in tariffs through its GMPD segment, with refund mechanisms remaining uncertain. Any clarity from management on tariff mitigation strategies or potential reimbursement timelines could move sentiment meaningfully. Additionally, the trajectory of GLP-1 drug distribution — which contributed roughly six percentage points to revenue growth in recent quarters — warrants close attention as newer oral formulations and expanded indications reshape demand patterns.

Capital allocation will also be in focus. With adjusted free cash flow guidance raised to $3.3 billion to $3.7 billion for fiscal 2026, and $1.0 billion deployed toward share repurchases year-to-date, investors will look for signals on whether the company intends to sustain or accelerate buyback activity. Finally, any preliminary fiscal 2027 outlook — particularly around EPS growth, segment profit targets, and free cash flow expectations — will be closely parsed. With consensus already projecting fiscal 2027 EPS of approximately $12.01, representing 11.5% growth, the market will be watching to see if management endorses or exceeds that trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations